Non-Hodgkin lymphoma and stem cell transplant

Category: Conditions & evidence · Editorial Review: Updated 20 October 2026 · 3 minute read

There are many lymphomas

Non-Hodgkin lymphoma is a group of diseases with different behavior and treatment options. Transplant may be appropriate in selected settings, but recommendations cannot be transferred from one lymphoma subtype to another. Confirm the exact pathology diagnosis before comparing programs. A specialist review of tissue may be more useful than immediately booking a procedure.

Clarify the available strategies

An autologous transplant uses the patient’s collected blood-forming cells after intensive treatment. A donor transplant has a different purpose and risk profile. Other approaches, including targeted therapies and some cellular immunotherapies, may also be relevant. CAR T-cell treatment is not another name for stem cell transplantation, even though both may be offered by the same hospital team.

What your consultation should address

Ask how previous response, the timing of relapse, imaging and overall health affect your options. Have the specialist explain why the proposed strategy fits your specific lymphoma rather than listing all treatments the hospital can provide. Ask what would change the recommendation if repeat pathology or staging differs from the original report.

Records and follow-through

Bring biopsy reports, available pathology material, scan files, treatment cycles and adverse reaction history. If transplantation is being considered abroad, ask who will arrange response imaging and manage problems after discharge. A useful written plan includes the next decision point and alternative steps if the disease does not respond as hoped.

Continue exploring

• Acute myeloid leukemia and transplantation
• Acute lymphoblastic leukemia and transplantation
• Multiple myeloma and autologous transplant
• Prepare your consultation checklist

Sources & further reading

• Primary patient information and research

Read alongside your treating specialist’s advice. Clinical eligibility, exact products and treatment plans require individual assessment.